Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a)

A cardiovascular, compound technology for reducing the risk of cardiovascular events and addressing unmet medical needs

Pending Publication Date: 2021-08-20
NOVARTIS AG
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0023] However, there is still an unmet medical need for an optimal therapeutic approach using ISIS 681257 to effectively and selectively reduce Apo(a) levels in humans while allowing patients to receive only the lowest required dose under optimal administration regimens ( included in patients at increased risk of cardiovascular events due to chronically elevated plasma Lp(a) levels)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a)
  • Method for reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a)
  • Method for reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a)

Examples

Experimental program
Comparison scheme
Effect test

example

[0429] The disclosure is further illustrated by the following examples, which should not be construed to limit the scope or spirit of the disclosure to the specific procedures described herein. It should be understood that these examples are provided to illustrate certain embodiments and are not intended to limit the scope of the present disclosure thereby. It should be further understood that various other embodiments, modifications and equivalents thereof may be employed, and those skilled in the art may conceive of these embodiments, modifications and equivalents thereof without departing from the spirit of the present disclosure and / or the accompanying Scope of the claims.

example 1

[0430] Example 1: A Randomized Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Effect of Lipoprotein(a) Lowering Using ISIS 681257 on Major Cardiovascular Events in Patients with Established Cardiovascular Disease

[0431] list of abbreviations

[0432]

[0433]

[0434]

[0435] Terminology

[0436]

[0437]

[0438] Purpose The study is a pivotal Phase 3 study designed to test the hypothesis that treatment with ISIS 68125780 mg subcutaneously (SC) once monthly (QM) will significantly reduce the risk of Lp(a ) levels of MACE (i.e., CV death, non-fatal myocardial infarction (MI), non-fatal stroke and urgent coronary revascularization) in patients receiving other than Lp(a) according to local guidelines CV risk factor-targeted treatment for reducing cardiovascular risk in patients with established CVD and elevated Lp(a).

[0439] Goals and Endpoints

[0440] Overview: The primary objective of this study was to demonstrate the role of T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure is directed to methods of reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a). Specifically, a method of reducing the risk of a cardiovascular event in a patient who has established cardiovascular disease with conjugated antisense compound ISIS 681257 or a salt thereof.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit and priority of U.S. Provisional Application No. 62 / 758,323, filed November 9, 2018, and U.S. Provisional Application No. 62 / 874,459, filed July 15, 2019, the entire contents of which are incorporated by reference in their entirety into this article. technical field [0003] The present disclosure relates to methods of reducing the risk of cardiovascular events with conjugated antisense compounds targeting apo(a). In particular, it relates to a method of reducing the risk of cardiovascular events with the conjugated antisense compound ISIS 681257 or a salt thereof in patients with established cardiovascular disease. Background technique [0004] The principle behind antisense technology is that antisense compounds hybridize to target nucleic acids and modulate the amount, activity and / or function of said target nucleic acids. For example, in certain instances, antisense compounds ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113A61K31/712A61K31/7125
CPCC12N15/113C12N2310/11C12N2310/315C12N2310/341C12N2310/3515C12N2310/322C12N2320/32C12N2310/345C12N2310/346C12N2310/3525A61K31/7105A61P9/00C12N2310/351C12N2320/30
Inventor A·列索戈尔邵青T·索伦
Owner NOVARTIS AG